ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

PTE PolarityTE Inc

0.241
0.00 (0.00%)
03 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
PolarityTE Inc NASDAQ:PTE NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.241 0.2325 0.235 0 01:00:00

PolarityTE to Report Q2 2022 Financial Results on August 11, 2022

01/08/2022 1:00pm

PR Newswire (US)


PolarityTE (NASDAQ:PTE)
Historical Stock Chart


From Jul 2022 to Jul 2024

Click Here for more PolarityTE Charts.

SALT LAKE CITY, Aug. 1, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ: PTE) today announced that it will report results for the quarter ended June 30, 2022, by press release on Thursday, August 11, 2022, at approximately 4:05 p.m. Eastern Time.

PolarityTE (PRNewsfoto/PolarityTE, Inc.)

In addition, the Company will host a conference call and webcast with Q&A on August 11, 2022, at 4:30 p.m. Eastern Time. The conference call can be accessed by calling 1-800-207-0148 with passcode 893469 and referencing "PolarityTE Second Quarter 2022 Business Update and Financial Results." A webcast of the conference call can be accessed by using the link below.

Earnings Call Webcast - CLICK HERE

A replay of the earnings conference call will be available for 30 days beginning approximately one hour after the conclusion of the call and can be found by visiting PolarityTE's website at https://www.polarityte.com/news-media/events, or by clicking on the link above.

About PolarityTE®

PolarityTE, Inc., headquartered in Salt Lake City, Utah, is a biotechnology company developing regenerative tissue products. PolarityTE's first regenerative tissue product is SkinTE®. PolarityTE has an open investigational new drug application (IND) for SkinTE® with the U.S. Food and Drug Administration (FDA) and is now pursuing the first of two pivotal studies on SkinTE® needed to support a biologics license application (BLA) for a chronic cutaneous ulcer indication. SkinTE® is available for investigational use only. Learn more at www.PolarityTE.com.

POLARITYTE, the POLARITYTE logo, SKINTE, and WHERE SELF REGENERATES SELF are registered trademarks of PolarityTE, Inc.

CONTACTS

Investors:
PolarityTE Investor Relations
ir@PolarityTE.com
(385) 831-5284

Media:
David Schull or Ignacio Guerrero-Ros
David.schull@russopartnersllc.com 
Ignacio.guerrero-ros@russopartnersllc.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/polarityte-to-report-q2-2022-financial-results-on-august-11-2022-301596394.html

SOURCE PolarityTE, Inc.

Copyright 2022 PR Newswire

1 Year PolarityTE Chart

1 Year PolarityTE Chart

1 Month PolarityTE Chart

1 Month PolarityTE Chart

Your Recent History

Delayed Upgrade Clock